Worse than expected for Astra Zeneca – Business World

The pharmaceutical company Astrazeneca reports earnings per share Core (Core EPS) of $ 0.83 (1.21) for the second quarter of 2016

Expectations were for 0 , $ 79, according to the consensus of Inquiry Financial. The range of expectations was between 0.71 to 0.88 dollars. Thus, the outcome was 5.1 percent better than expected.

reported earnings per share were $ 0.00 (0.55) compared to the expected value of +0.23 dollars.

On the reported level, earnings before tax -30 million ($ 658), against the anticipated 392 million. Net profit stood at -31 million ($ 697) with an expected value of $ 288 million.

Core operating profit was $ 1.406 billion (1813), compared with expectations of $ 1.418 billion. Profit before tax stood at $ 1.24 billion (1679) with expectations of $ 1.189 billion. Net income was $ 1.028 billion (1520) and an expected value of $ 997 million.

The total revenue was $ 5.603 billion (6307). In constant currency backed sales by 10 percent in the quarter (+2) compared with the same period last year.

The total revenue is distributed on $ 5.469 billion in product sales (5,836) and $ 134 million (471) in outsourcing revenues, which include include milestone payments and sales of rights. The expected product sales stood at $ 5.54 billion.

The Board has recommended a dividend for the first half of 2016 of $ 0.90 (0.90).

Astrazeneca track continued to earnings per the stock core (core EPS) in 2016 will fall by a low to mid single digit at constant exchange rates (CER).

It is clear from the report.

the revenue is expected to continue to go down with a low to mid single digit at constant exchange rates (CER).

the pharmaceutical company AstraZeneca sales of ulcer medicine Nexium totaled $ 562 million (647) during the second quarter in 2016.

analysts had predicted a sales of Nexium at $ 458 million, according to SIX News / inquiry Financials survey.

Antipsykotikamedlet Seroquel (Seroquel XR) during the period had a turnover of $ 225 million (264). The expected value was $ 217 million.

Crestor statin reported revenue of $ 926 million (1,310) compared with expectations at 1.062 billion US dollars.

Asthma medication Symbicort reached sales of $ 803 million dollar (842). Analysts had expected sales of $ 775 million. Pulmicort had sales of $ 239 million in the quarter (232) with expectations at 268 million US dollars.

The anticoagulant Brilinta / Brilique, which is expected to be AstraZeneca’s next big seller, reported sales of $ 214 million (144) quarter. The expected sales of Brilinta / Brilique was 202 million dollars.

Breast cancer drug Arimidex recorded sales of $ 62 million (64) compared to an expected value of 60 million dollars.

lung cancer drug Tagrisso sales totaled $ 92 million in the first quarter.